Strontium Compositions Targeting Type C Nociceptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topical treatments for pain, pruritus, and inflammation often lack specificity, causing numbness and loss of function due to their non-selective action on sensory nerves, and struggle to effectively manage chronic and neuropathic conditions.
Innovation Solution
The development of strontium-containing compositions, including strontium chloride, sulfate, or carbonate combined with beta hydroxybutyrate, cysteine-based antioxidants, and polyhydroxyphenols, which selectively target Type C nociceptors to inhibit pain and inflammation while preserving normal tactile sensations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If topical local anesthetics like lidocaine are used to suppress sensory irritation, then pain and itching are reduced, but numbness and loss of normal tactile sensation occur due to non-selective action on all sensory nerves
Solution Approach 1:
The patent applies local quality by making strontium selectively target only Type C nociceptors while leaving other sensory nerves unaffected. This specificity is achieved through strontium's unique biochemical interaction with TCN channels, allowing pain and itching suppression without causing numbness or loss of normal tactile sensation.
Solution Approach 2:
The patent segments the sensory nerve population by specifically targeting Type C nociceptors rather than all sensory nerves. This segmentation is accomplished through strontium's selective binding to TCN channels, which are uniquely expressed on Type C fibers, thereby differentiating between harmful pain-transmitting nerves and beneficial tactile-transmitting nerves.
2Reliability
If existing topical drugs are used for chronic and neuropathic conditions, then some symptom relief is achieved, but effectiveness is limited due to lack of specificity and mechanism targeting
Solution Approach 1:
The patent achieves universality by demonstrating that strontium's mechanism of selectively suppressing Type C nociceptor activation applies across multiple pain conditions including acute pain, chronic pain, neuropathic pain, and inflammatory conditions. This single mechanism provides broad adaptability across different pain etiologies without requiring condition-specific formulations.
Data Source
AI summary
Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied.